Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oncologists spent 3 minutes less with minority patients on scan results

Smith CB et al. PallOnc 2018, Abstract 19

Key clinical point: Oncologists spent on average 3 minutes less with minority patients than with nonminority patients discussing a scan result related to an advanced cancer.

Major finding: Adjusted discussion time was 13.5 minutes for minority patients versus 16.5 minutes for nonminority patients.

Study details: Analysis of audio recordings of discussions between 142 patients and 22 oncologists at four hospitals.

Disclosures: The research was supported by the Patient Centered Outcomes Research Institute. The presenting author reported honoraria and a consulting or advisory role with Teva.

Read the article here.

Citation:

Smith CB et al. PallOnc 2018, Abstract 19.

This Week's Must Reads

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.

Must Reads in Patient & Survivor Care

auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824

Pregnancy does not increase melanoma recurrence risk, DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.